Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators.

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.

PMID:
23710902
[PubMed - indexed for MEDLINE]
Free Article
2.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
[PubMed - indexed for MEDLINE]
3.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
[PubMed - indexed for MEDLINE]
4.

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group.

Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x.

PMID:
21205128
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group.

Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x.

PMID:
20590735
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.

Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group.

Clin J Pain. 2009 Jun;25(5):376-85. doi: 10.1097/AJP.0b013e318196d2b6.

PMID:
19454870
[PubMed - indexed for MEDLINE]
7.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

PMID:
18819705
[PubMed - indexed for MEDLINE]
8.
9.

Patient perception and use of an insulin injector/glucose monitor combined device.

Bode B, Shelmet J, Gooch B, Hassman DR, Liang J, Smedegaard JK, Skovlund S, Berg B, Lyness W, Schneider SH; InDuo Study Group.

Diabetes Educ. 2004 Mar-Apr;30(2):301-9.

PMID:
15095520
[PubMed - indexed for MEDLINE]
10.

Preference and resource utilization in elderly patients: InnoLet versus vial/syringe.

Shelmet J, Schwartz S, Cappleman J, Peterson G, Skovlund S, Lytzen L, Nicklasson L, Liang J, Lyness W; InnoLet Study Group.

Diabetes Res Clin Pract. 2004 Jan;63(1):27-35.

PMID:
14693410
[PubMed - indexed for MEDLINE]
11.

Nonbinding inhibitory antiinsulin receptor antibodies. A new type of autoantibodies in human diabetes.

Boden G, Fujita-Yamaguchi Y, Shimoyama R, Shelmet JJ, Tappy L, Rezvani I, Owen OE.

J Clin Invest. 1988 Jun;81(6):1971-8.

PMID:
2968369
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Ethanol causes acute inhibition of carbohydrate, fat, and protein oxidation and insulin resistance.

Shelmet JJ, Reichard GA, Skutches CL, Hoeldtke RD, Owen OE, Boden G.

J Clin Invest. 1988 Apr;81(4):1137-45.

PMID:
3280601
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The management of non-insulin-dependent diabetes mellitus.

Krosnick A, Shelmet JJ.

Clin Ther. 1988;10(2):146-57. Review.

PMID:
3078902
[PubMed - indexed for MEDLINE]
14.

Treat human diabetes with human insulin.

Shelmet JJ.

N J Med. 1987 Oct;84(10):723-4. No abstract available.

PMID:
3317140
[PubMed - indexed for MEDLINE]
15.

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.

Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE.

N Engl J Med. 1986 Jun 26;314(26):1686-9. No abstract available.

PMID:
2872592
[PubMed - indexed for MEDLINE]
16.

Effects of anti-insulin receptor antibodies (AIRA) on downregulation and turnover of insulin receptors on cultured hepatocytes.

Shimoyama R, Shelmet JJ, Savage CR Jr, Boden G.

Diabetes. 1986 Jan;35(1):28-32.

PMID:
3510136
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk